摘要
目的:研究胸腺肽α1联合化疗治疗老年晚期胃癌的疗效及对患者基质金属蛋白酶(MMP)-2、MMP-9的影响。方法:选取我院收治的老年晚期胃癌患者92例,按随机数字表法分为对照组和研究组,各46例。对照组给予XELOX化疗方案治疗,在此基础上,研究组加用胸腺肽α1(40 mg+0.9%氯化钠注射液500 mL静脉滴注,qd)治疗。比较两组临床疗效、不良反应情况,并观察两组治疗前后的免疫功能及MMPs水平的差异。结果:研究组临床疗效高于对照组,差异有统计学意义(P <0.05);治疗后,研究组CD4+、CD8+及CD4+/CD8+均高于对照组,MMP-2、MMP-9均低于对照组,差异有统计学意义(P <0.05);治疗期间治疗组不良反应发生率低于对照组,差异有统计学意义(P <0.05)。结论:胸腺肽α1联合化疗治疗老年晚期胃癌的疗效确切,可有效改善患者的免疫功能,降低MMP-2、MMP-9表达水平,且安全性高。
Objective:To study the efficacy of thymosinα1 combined with chemotherapy in the treatment of advanced gastric cancer in elderly patients and its effect on matrix metalloproteinases(MMP)-2 and MMP-9.Methods:92 elderly patients with advanced gastric cancer admitted to our hospital were selected and randomly divided into a control group and a study group,46 cases each.The patients in the control group were given XELOX chemotherapy.On this basis,the patients in the study group were given thymosinα1(40 mg+0.9%sodium chloride injection 500 mL,intravenous drip,qd)treatment.The clinical efficacy and adverse reactions were compared between the two groups,and the immune functions and the difference in MMPs levels before and after treatment in the two groups were observed.Results:The clinical efficacy in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CD4+,CD8+and CD4+/CD8+in the study group were higher than those in the control group,while the levels of MMP-2 and MMP-9 in the study group were lower than those in the control group,with statistically significant differences(P<0.05).The incidence of adverse reactions during the treatment in the treatment group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:Thymosinα1 combined with chemotherapy is effective in the treatment of advanced gastric cancer in the elderly patients,which can effectively improve the immune functions of the patients and reduce the expression levels of MMP-2 and MMP-9,and has high safety.
作者
郭宝中
Guo Bao-zhong(Affi liated Hospital of Huanghe Science and Technology University,Zhengzhou Henan 450000,China)
出处
《中国合理用药探索》
CAS
2019年第7期54-56,59,共4页
Chinese Journal of Rational Drug Use
关键词
胸腺肽Α1
化疗
老年晚期胃癌
Thymosinα1
Chemotherapy
Elderly Advanced Gastric Cancer
作者简介
郭宝中,男,主治医师。研究方向:消化系统疾病。E-mail:zhengainideyun@163.com
